Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Thomas, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille, Garg, Mamta, Quach, Hang, Sia, Hanlon, George, Anup, Konstantinova, Tatiana, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, van de Velde, Helgi, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636327/
https://www.ncbi.nlm.nih.gov/pubmed/35594559
http://dx.doi.org/10.1182/bloodadvances.2021006713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636327/
https://www.ncbi.nlm.nih.gov/pubmed/35594559
http://dx.doi.org/10.1182/bloodadvances.2021006713

Ejemplares similares